Dr. Steve Elias performed the procedure at the Center for Vein Disease, part of the Englewood Health Network in Englewood, New Jersey.
“The Sclerosafe procedure takes less than 30 minutes, requires only one small needle stick, and patients can resume normal activity immediately. We are constantly looking for new treatments to improve our patient’s quality of life. Sclerosafe is the latest addition to our armament of advanced treatment options for vein and vascular conditions,” Elias said in a news release.
The FDA cleared ScleroSafe in June. The company has already received approval for ScleroSafe in multiple regions, including Europe, Australia, Southeast Asia, and South America.
Kfar Saba, Israel–based VVT Medical says it specifically created ScleroSafe to provide efficient, non-thermal, non-tumescent treatment and management of varicosities in superficial veins. Its inverse-action dual syringe injects the ECA substance into the vein through one syringe while simultaneously aspirating blood and substance residuals through the second syringe. ScleroSafe accomplishes all of these actions within a single motion and with single-hand operation.
“We take great pride in leading the way in the development of a varicose vein solution. ScleroSafe holds the promise of transforming varicose vein treatment, providing patients with a safe, effective, and straightforward option” said Erez Tetro, CEO of VVT Medical. “We firmly believe that our product has the ability to bring about a positive change in the lives of countless individuals across the United States and worldwide.”